Date: 2018-08-16
Type of information: Private placement
Company: Krystal Biotech (USA - PA)
Investors: Frazier Healthcare Partners (USA - WA)
Amount: $10 million
Funding type: private placement
Planned used:
- Net proceeds from this offering are expected to be used to continue funding the research and development of Krystal’s pipeline product candidates.
Others:
- • On August 16, 2018, Krystal Biotech announced that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 per share. The private placement will yield gross proceeds of $10 million and is expected to close on August 17, 2018, subject to the satisfaction of customary closing conditions. Chardan acted as the sole placement agent in the transaction.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
